Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Chronic hepatitis B (CHB) remains a major global health challenge, with functional cure achieved in only a small subset of patients. Current oral antiviral agents effectively suppress viral ...

Scientists discovered a way to block hepatitis B infection using an anticancer drug, offering hope for new treatments.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment portfolio and pipeline at the Conference ...

Hepatitis B can lead to liver disease. But we can prevent and manage this viral infection. Here’s what we know about the ...

Vir Biotechnology may be pushing ahead with its combination therapy in hepatitis D, but it's pausing further development in ...

Famciclovir. A prodrug of penciclovir, famciclovir does not have a major role in the treatment of chronic hepatitis B because of its low efficacy compared with lamivudine. Adefovir dipivoxil.

To facilitate the achieving of the goal of “eliminating viral hepatitis as a major public health threat by 2030” set by the World Health Organization, the Chinese Society of Hepatology together with ...

Worldwide, hepatitis B is thought to be the second deadliest infection; about 5% of the global population are infection and it can lead to liver cancer. | Microbiology ...

The American Gastroenterological Association (AGA) has released an updated clinical practice guideline on the prevention of ...

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025IMC-M113V was well ...

The following is a summary of "Impact of HBsAg reduction via siRNA treatment on natural and vaccine (BRII-179)-induced ...